Optimi Health Corp.
No SEC Form 4 filings for $OPTH in the last 30 days.
See all $OPTH insider activity →Optimi Health Corp. (OPTI) has produced a GMP batch of MDMA for use in a proposed Canadian Phase 3 PTSD trial, an Israeli trial, and Australian commercial exports. The company aims to supply these markets by the end of 2026, marking a shift towards commercial and late-stage clinical supply.
Optimi Health (OPTH) plans to start a Phase 3 trial in 2027 for its synthetic MDMA-assisted PTSD therapy, enrolling up to 100 participants in Canada. The trial will evaluate efficacy using the CAPS-5 scale. OPTH's MDMA is already prescribed in Australia and accessible in Canada. The company's stock is currently trading at $4.84, down 5.56%.
Optima Health PLC (GB00BRSCY602) disclosed a major holding notification. Octopus Investments Limited crossed a voting rights threshold on 15-Sep-2026, with details submitted to the London Stock Exchange on 16-Sep-2026. The filing includes voting rights and financial instrument details, as required by UK regulations.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning OPTH (Optimi Health Corp.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent OPTH coverage spans financial news, technology and corporate actions.
Optimi Health Corp. (OPTI) has produced a GMP batch of MDMA for use in a proposed Canadian Phase 3 PTSD trial, an Israeli trial, and Australian commercial exports. The company aims to supply these markets by the end of 2026, marking a shift towards commercial and late-stage clinical supply.
Potential upside if Phase 3 data are positive, supporting future regulatory filing and market expansion.
Potential shift in control may influence future strategic decisions and share price.
AlphAI scores every news story that mentions OPTH with an AI model for sentiment and relevance, and aggregates insider trades from Optimi Health Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Optimi Health Corp. (OPTI) has produced a GMP batch of MDMA for use in a proposed Canadian Phase 3 PTSD trial, an Israeli trial, and Australian commercial exports. The company aims to supply these markets by the end of 2026, marking a shift towards commercial and late-stage clinical supply.
1 min readOptimi Health (OPTH) plans to start a Phase 3 trial in 2027 for its synthetic MDMA-assisted PTSD therapy, enrolling up to 100 participants in Canada. The trial will evaluate efficacy using the CAPS-5 scale. OPTH's MDMA is already prescribed in Australia and accessible in Canada. The company's stock is currently trading at $4.84, down 5.56%.
2 min readOptima Health PLC (GB00BRSCY602) disclosed a major holding notification. Octopus Investments Limited crossed a voting rights threshold on 15-Sep-2026, with details submitted to the London Stock Exchange on 16-Sep-2026. The filing includes voting rights and financial instrument details, as required by UK regulations.
1 min read
